MiMedx Group (NASDAQ:MDXG) Rating Lowered to "Buy" at StockNews.com

MiMedx Group (NASDAQ:MDXG - Get Free Report) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a note issued to investors on Wednesday.

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Trading Down 1.5 %

MiMedx Group stock traded down $0.10 during midday trading on Wednesday, hitting $6.58. 157,691 shares of the stock were exchanged, compared to its average volume of 692,671. The company has a fifty day simple moving average of $7.69 and a two-hundred day simple moving average of $8.03. The stock has a market capitalization of $969.67 million, a PE ratio of 11.96 and a beta of 1.74. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The business had revenue of $92.91 million for the quarter, compared to analysts' expectations of $89.42 million. Equities research analysts anticipate that MiMedx Group will post 0.3 EPS for the current fiscal year.

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now directly owns 310,836 shares of the company's stock, valued at $2,452,496.04. This represents a 1.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO William Frank Iv Hulse sold 54,596 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the sale, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. The trade was a 11.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock worth $1,130,312 over the last quarter. 1.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On MiMedx Group

Institutional investors and hedge funds have recently bought and sold shares of the company. Sowell Financial Services LLC bought a new stake in shares of MiMedx Group during the 1st quarter worth $115,000. Harbor Capital Advisors Inc. boosted its position in MiMedx Group by 4.2% during the first quarter. Harbor Capital Advisors Inc. now owns 1,043,676 shares of the company's stock valued at $7,932,000 after acquiring an additional 42,288 shares during the last quarter. Rhumbline Advisers grew its stake in MiMedx Group by 1.4% during the first quarter. Rhumbline Advisers now owns 177,156 shares of the company's stock worth $1,346,000 after purchasing an additional 2,436 shares during the period. Wellington Management Group LLP lifted its position in shares of MiMedx Group by 22.8% during the 4th quarter. Wellington Management Group LLP now owns 389,706 shares of the company's stock valued at $3,749,000 after acquiring an additional 72,432 shares during the period. Finally, Phocas Financial Corp. acquired a new stake in shares of MiMedx Group in the 4th quarter valued at about $2,016,000. Institutional investors own 79.15% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.